"This is a story of bench-to-bedside therapy, with a novel cell therapy designed in the laboratories of Massachusetts General Hospital and translated for patient use within five years, to meet an urgent need," said co-author Bryan Choi.
"The CAR-T platform has revolutionized how we think about treating patients with cancer, but solid tumors like glioblastoma have remained challenging to treat... Our approach combines two forms of therapy, allowing us to treat glioblastoma in a broader, potentially more effective way," said Bryan Choi.
The new approach is a result of years of collaboration and innovation springing from the lab of Marcela Maus, director of the Cellular Immunotherapy Program and an associate professor at the Medical School.
[
add
]
[
|
|
...
]